BACKGROUND: Tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS) is caused by dominant mutations in the TNFRSF1A gene. In typical cases TRAPS begins early in childhood and is characterised by high and remittent fever over a period of 1-4 weeks or longer, accompanied by systemic and local inflammation. CASE REPORTS: Patient 1 presented with recurrent episodes of weakness, migrating myalgias, arthralgias, exanthema, and chest pain lasting for 1-4 weeks, but without any fever over an initial period of 4 years at least. Diagnosis of TRAPS was confirmed by the heterozygous mutation Y20H in TNFRSF1A. Patient 2, a 23 year old woman never had any symptoms indicative of TRAPS. Genetic evaluation of all members of her family with a TRAPS index patient disclosed the T50M mutation in TNFRSF1A. A medical check up showed proteinuria, and renal biopsy disclosed AA amyloidosis. CONCLUSIONS: TRAPS associated mutations can induce considerable inflammation that is not necessarily accompanied by fever. Even monosymptomatic severe amyloidosis can occur in these patients. Genetic counselling and appropriate management to prevent or mitigate amyloidosis may be necessary.
BACKGROUND:Tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS) is caused by dominant mutations in the TNFRSF1A gene. In typical cases TRAPS begins early in childhood and is characterised by high and remittent fever over a period of 1-4 weeks or longer, accompanied by systemic and local inflammation. CASE REPORTS: Patient 1 presented with recurrent episodes of weakness, migrating myalgias, arthralgias, exanthema, and chest pain lasting for 1-4 weeks, but without any fever over an initial period of 4 years at least. Diagnosis of TRAPS was confirmed by the heterozygous mutation Y20H in TNFRSF1A. Patient 2, a 23 year old woman never had any symptoms indicative of TRAPS. Genetic evaluation of all members of her family with a TRAPS index patient disclosed the T50M mutation in TNFRSF1A. A medical check up showed proteinuria, and renal biopsy disclosed AA amyloidosis. CONCLUSIONS: TRAPS associated mutations can induce considerable inflammation that is not necessarily accompanied by fever. Even monosymptomatic severe amyloidosis can occur in these patients. Genetic counselling and appropriate management to prevent or mitigate amyloidosis may be necessary.
Authors: A Rösen-Wolff; H W Kreth; S Hofmann; K Höhne; G Heubner; D Möbius; F Zintl; M Gahr; J Roesler Journal: Eur J Haematol Date: 2001-08 Impact factor: 2.997
Authors: Catherine Dodé; Bouke P C Hazenberg; Christophe Pêcheux; Daniel Cattan; Bruno Moulin; Anne Barthélémy; Marie-Claire Gubler; Marc Delpech; Gilles Grateau Journal: Nephrol Dial Transplant Date: 2002-07 Impact factor: 5.992
Authors: Keith M Hull; Nitza Shoham; Jae Jin Chae; Ivona Aksentijevich; Daniel L Kastner Journal: Curr Opin Rheumatol Date: 2003-01 Impact factor: 5.006
Authors: Keith M Hull; Elizabeth Drewe; Ivona Aksentijevich; Harjot K Singh; Kondi Wong; Elizabeth M McDermott; Jane Dean; Richard J Powell; Daniel L Kastner Journal: Medicine (Baltimore) Date: 2002-09 Impact factor: 1.889
Authors: Isabelle Touitou; Suzanne Lesage; Michael McDermott; Laurence Cuisset; Hal Hoffman; Catherine Dode; Nitza Shoham; Ebun Aganna; Jean-Pierre Hugot; Carol Wise; Hans Waterham; Denis Pugnere; Jacques Demaille; Cyril Sarrauste de Menthiere Journal: Hum Mutat Date: 2004-09 Impact factor: 4.878
Authors: Hella Luksch; Stefan Winkler; Michael C Heymann; Felix Schulze; Sigrun R Hofmann; Joachim Roesler; Angela Rösen-Wolff Journal: Curr Rheumatol Rep Date: 2015-07 Impact factor: 4.592
Authors: Divya Shakti; Rebecca Hehn; Kimberly Gauvreau; Robert P Sundel; Jane W Newburger Journal: J Am Heart Assoc Date: 2014-11-07 Impact factor: 5.501
Authors: Laura Barnabei; Emmanuel Laplantine; William Mbongo; Frédéric Rieux-Laucat; Robert Weil Journal: Front Immunol Date: 2021-08-09 Impact factor: 7.561